Amarin Corporation plc (Nasdaq:

), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today presented additional data on Vascepa® (icosapent ethyl) and its effect on lipoprotein particle concentration from the Phase 3 ANCHOR study at the National Lipid Association (NLA) 2013 Annual Scientific Session in Las Vegas, Nevada. The data presentation titled, "Effects of Icosapent Ethyl on Lipoprotein Particle Concentration and the Fatty Acid Desaturation Index in Statin-treated Patients with Persistent High Triglycerides (the ANCHOR Study)", reported that Vascepa 4 g/day, when added to optimized statin therapy for 12 weeks, significantly reduced median particle concentrations of total very-low-density lipoprotein (VLDL) by 12.2%, total low-density lipoprotein (LDL) by 7.7%, and small LDL particles by 13.5% across the 12 week treatment period, compared with placebo. The ANCHOR study, authored by Christie M. Ballantyne, M.D. and colleagues, investigated Vascepa as a treatment for high triglycerides (≥200 and <500mg/dL) in 702 patients with mixed dyslipidemia (two or more lipid disorders) on optimized background statin therapy who were at LDL-C (low-density lipoprotein cholesterol) goal, and who were also at high risk of cardiovascular disease. The original results, which were